These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 16928523)

  • 21. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Piao W; Wang Y; Adachi Y; Yamamoto H; Li R; Imsumran A; Li H; Maehata T; Ii M; Arimura Y; Lee CT; Shinomura Y; Carbone DP; Imai K
    Mol Cancer Ther; 2008 Jun; 7(6):1483-93. PubMed ID: 18566219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
    Hopfner M; Sutter AP; Huether A; Baradari V; Scherubl H
    World J Gastroenterol; 2006 Sep; 12(35):5635-43. PubMed ID: 17007015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Scotlandi K; Manara MC; Nicoletti G; Lollini PL; Lukas S; Benini S; Croci S; Perdichizzi S; Zambelli D; Serra M; García-Echeverría C; Hofmann F; Picci P
    Cancer Res; 2005 May; 65(9):3868-76. PubMed ID: 15867386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    Moser C; Schachtschneider P; Lang SA; Gaumann A; Mori A; Zimmermann J; Schlitt HJ; Geissler EK; Stoeltzing O
    Eur J Cancer; 2008 Jul; 44(11):1577-86. PubMed ID: 18445520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    Ou DL; Lee BS; Chang YC; Lin LI; Liou JY; Hsu C; Cheng AL
    PLoS One; 2013; 8(6):e66589. PubMed ID: 23818948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
    Esparís-Ogando A; Ocaña A; Rodríguez-Barrueco R; Ferreira L; Borges J; Pandiella A
    Ann Oncol; 2008 Nov; 19(11):1860-9. PubMed ID: 18641009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
    Attias-Geva Z; Bentov I; Fishman A; Werner H; Bruchim I
    Gynecol Oncol; 2011 May; 121(2):383-9. PubMed ID: 21295335
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
    Ioannou N; Seddon AM; Dalgleish A; Mackintosh D; Modjtahedi H
    BMC Cancer; 2013 Jan; 13():41. PubMed ID: 23367880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
    Cell Oncol (Dordr); 2011 Jun; 34(3):245-59. PubMed ID: 21538027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Zumsteg A; Caviezel C; Pisarsky L; Strittmatter K; García-Echeverría C; Hofmann F; Christofori G
    Mol Cancer Res; 2012 Jun; 10(6):800-9. PubMed ID: 22562956
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    Hamilton N; Austin D; Márquez-Garbán D; Sanchez R; Chau B; Foos K; Wu Y; Vadgama J; Pietras R
    Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Browne BC; Eustace AJ; Kennedy S; O'Brien NA; Pedersen K; McDermott MS; Larkin A; Ballot J; Mahgoub T; Sclafani F; Madden S; Kennedy J; Duffy MJ; Crown J; O'Donovan N
    Breast Cancer Res Treat; 2012 Dec; 136(3):717-27. PubMed ID: 23117852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Pennarun B; Kleibeuker JH; Oenema T; Stegehuis JH; de Vries EG; de Jong S
    Anal Cell Pathol (Amst); 2010; 33(5):229-44. PubMed ID: 20978316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Bielen A; Perryman L; Box GM; Valenti M; de Haven Brandon A; Martins V; Jury A; Popov S; Gowan S; Jeay S; Raynaud FI; Hofmann F; Hargrave D; Eccles SA; Jones C
    Mol Cancer Ther; 2011 Aug; 10(8):1407-18. PubMed ID: 21659463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    Gohr K; Hamacher A; Engelke LH; Kassack MU
    BMC Cancer; 2017 Nov; 17(1):711. PubMed ID: 29100507
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
    Gariboldi MB; Ravizza R; Monti E
    Biochem Pharmacol; 2010 Aug; 80(4):455-62. PubMed ID: 20488164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
    Tsushima H; Morimoto S; Fujishiro M; Yoshida Y; Hayakawa K; Hirai T; Miyashita T; Ikeda K; Yamaji K; Takamori K; Takasaki Y; Sekigawa I; Tamura N
    Autoimmunity; 2017 Aug; 50(5):329-335. PubMed ID: 28682648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.